[
  {
    "ts": null,
    "headline": "Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down",
    "summary": "Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.",
    "url": "https://finnhub.io/api/news?id=a07f01136540193552d918c755e0eaf47a3bcddf9224c91c09e593752c76183b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745957592,
      "headline": "Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down",
      "id": 134141940,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.",
      "url": "https://finnhub.io/api/news?id=a07f01136540193552d918c755e0eaf47a3bcddf9224c91c09e593752c76183b"
    }
  },
  {
    "ts": null,
    "headline": "Equity Markets Higher Despite Weak US Consumer Confidence Data",
    "summary": "US benchmark equity indexes are on track to close higher on Tuesday, despite April's US consumer con",
    "url": "https://finnhub.io/api/news?id=181116646d62b72e40e68fae0990f47178bd4103e75653c929a07f873d72ed50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745955751,
      "headline": "Equity Markets Higher Despite Weak US Consumer Confidence Data",
      "id": 134141941,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes are on track to close higher on Tuesday, despite April's US consumer con",
      "url": "https://finnhub.io/api/news?id=181116646d62b72e40e68fae0990f47178bd4103e75653c929a07f873d72ed50"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides",
    "summary": "On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported sales of $3.03 billion, down 4%, missing the consensus of $3.29 billion. In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s Eylea HD Could Be Headed For Major Expan",
    "url": "https://finnhub.io/api/news?id=3297a459ade0ce29e6293c86e22b47c13747742607ec9f8f1902529e315d0588",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745952747,
      "headline": "Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides",
      "id": 134141942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported sales of $3.03 billion, down 4%, missing the consensus of $3.29 billion. In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s Eylea HD Could Be Headed For Major Expan",
      "url": "https://finnhub.io/api/news?id=3297a459ade0ce29e6293c86e22b47c13747742607ec9f8f1902529e315d0588"
    }
  },
  {
    "ts": null,
    "headline": "Why Regeneron (REGN) Stock Is Falling Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall, this quarter could have been better.",
    "url": "https://finnhub.io/api/news?id=f0ee58c1a9d3907f258596f89e1d611744bbd877f07b94e6933e0a954c7ee0e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745952214,
      "headline": "Why Regeneron (REGN) Stock Is Falling Today",
      "id": 134141943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall, this quarter could have been better.",
      "url": "https://finnhub.io/api/news?id=f0ee58c1a9d3907f258596f89e1d611744bbd877f07b94e6933e0a954c7ee0e2"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=128f4b7140f352deb0524a6961abd361f76a577fa6253014704a8bff0da81a3c",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745948940,
      "headline": "Health Care Roundup: Market Talk",
      "id": 134152074,
      "image": "",
      "related": "REGN",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=128f4b7140f352deb0524a6961abd361f76a577fa6253014704a8bff0da81a3c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates",
    "summary": "Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug—that missed analysts' estimates by a wide margin.",
    "url": "https://finnhub.io/api/news?id=301cab8e7409a15f2c445baf5b3cb74bcdea45143395074774d42af22da07e82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745947955,
      "headline": "Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates",
      "id": 134141944,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug—that missed analysts' estimates by a wide margin.",
      "url": "https://finnhub.io/api/news?id=301cab8e7409a15f2c445baf5b3cb74bcdea45143395074774d42af22da07e82"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down",
    "summary": "REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.",
    "url": "https://finnhub.io/api/news?id=1752cb3208ab3894d09f3a7d60379cdd209f4b8f513be125b1b24ca9d12b0e51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745947320,
      "headline": "Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down",
      "id": 134141945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.",
      "url": "https://finnhub.io/api/news?id=1752cb3208ab3894d09f3a7d60379cdd209f4b8f513be125b1b24ca9d12b0e51"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=974f18b78ae225b8860e4c4ae248be6d37b98a888f020cbd6e266ff6569a2471",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745944200,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 134152105,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=974f18b78ae225b8860e4c4ae248be6d37b98a888f020cbd6e266ff6569a2471"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More",
    "summary": "Major U.S. stock indexes were higher at midday as markets awaited more information about potential White House tariff deals.",
    "url": "https://finnhub.io/api/news?id=a6ddea9c4d6f44545b91618bccb6817c4fbca10f2037e87c9d5747cd3df871b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745942037,
      "headline": "Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More",
      "id": 134131214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Major U.S. stock indexes were higher at midday as markets awaited more information about potential White House tariff deals.",
      "url": "https://finnhub.io/api/news?id=a6ddea9c4d6f44545b91618bccb6817c4fbca10f2037e87c9d5747cd3df871b4"
    }
  },
  {
    "ts": null,
    "headline": "SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO",
    "summary": "Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on SWTX and MKGAF stock post deal.",
    "url": "https://finnhub.io/api/news?id=9a252710b61b998d96f2d09cc804f1cd2b2ecace76754cace4f2800ee54a189d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745941611,
      "headline": "SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO",
      "id": 134135895,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201085783/image_2201085783.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on SWTX and MKGAF stock post deal.",
      "url": "https://finnhub.io/api/news?id=9a252710b61b998d96f2d09cc804f1cd2b2ecace76754cace4f2800ee54a189d"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Stock Plummets After Earnings Miss",
    "summary": "First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts’ expectations.",
    "url": "https://finnhub.io/api/news?id=aa49354009a6eba4c3890c3326875eae3c78d014680d797dcb49dd531feff10f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745936940,
      "headline": "Regeneron Stock Plummets After Earnings Miss",
      "id": 134131492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts’ expectations.",
      "url": "https://finnhub.io/api/news?id=aa49354009a6eba4c3890c3326875eae3c78d014680d797dcb49dd531feff10f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Crashes 9% After Eylea Miss Drags Its Earnings Down",
    "summary": "Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.",
    "url": "https://finnhub.io/api/news?id=79e2f87243c467126c4a7f1fa631320b7038891bd3d0841779a67b35d7e1e732",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745934132,
      "headline": "Regeneron Crashes 9% After Eylea Miss Drags Its Earnings Down",
      "id": 134131493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.",
      "url": "https://finnhub.io/api/news?id=79e2f87243c467126c4a7f1fa631320b7038891bd3d0841779a67b35d7e1e732"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say",
    "summary": "The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=fd87050ea166199dfaf5f6f0fb065fd3702249984035de9d30b33de03a1f1f22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745933424,
      "headline": "Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say",
      "id": 134131494,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=fd87050ea166199dfaf5f6f0fb065fd3702249984035de9d30b33de03a1f1f22"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ETCompany ParticipantsRyan Crowe - SVP, IRLeonard...",
    "url": "https://finnhub.io/api/news?id=41e14fb6ddc171066eaf835a940cb374313dada079750385d6b04f89fdef9dd0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745929800,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript",
      "id": 134131946,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ETCompany ParticipantsRyan Crowe - SVP, IRLeonard...",
      "url": "https://finnhub.io/api/news?id=41e14fb6ddc171066eaf835a940cb374313dada079750385d6b04f89fdef9dd0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's first-quarter results miss on lower Eylea demand",
    "summary": "(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied approval for a more convenient version of the eye therapy.  Shares of Regeneron were down nearly 8%.  Regeneron has been looking to switch patients to a higher-dose version of the drug, branded as Eylea HD, to stymie the loss in market share to cheaper versions and rivals.",
    "url": "https://finnhub.io/api/news?id=619175c09656e0a2aa46ecb936a933155565d06aea4e55fe18fe5b4035e10f2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745929678,
      "headline": "Regeneron's first-quarter results miss on lower Eylea demand",
      "id": 134131495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied approval for a more convenient version of the eye therapy.  Shares of Regeneron were down nearly 8%.  Regeneron has been looking to switch patients to a higher-dose version of the drug, branded as Eylea HD, to stymie the loss in market share to cheaper versions and rivals.",
      "url": "https://finnhub.io/api/news?id=619175c09656e0a2aa46ecb936a933155565d06aea4e55fe18fe5b4035e10f2c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates",
    "summary": "Regeneron (REGN) delivered earnings and revenue surprises of -2.49% and 7.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=c7d943cfbabbaf363e1d1613f78990c3516ecfbeb989682f1d79c2014b2ccdb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745926802,
      "headline": "Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates",
      "id": 134131496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) delivered earnings and revenue surprises of -2.49% and 7.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=c7d943cfbabbaf363e1d1613f78990c3516ecfbeb989682f1d79c2014b2ccdb0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Q1 Earnings Snapshot",
    "summary": "The Tarrytown, New York-based company said it had profit of $7.27 per share. Earnings, adjusted for one-time gains and costs, came to $8.22 per share. The results fell short of Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=63f1344de60a0bec023585dd4d803f118a8258268a179b277571ff64e3ff9d72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745923236,
      "headline": "Regeneron: Q1 Earnings Snapshot",
      "id": 134131497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The Tarrytown, New York-based company said it had profit of $7.27 per share. Earnings, adjusted for one-time gains and costs, came to $8.22 per share. The results fell short of Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=63f1344de60a0bec023585dd4d803f118a8258268a179b277571ff64e3ff9d72"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=b94400337c2f6fa646f7a59b7eba5a7ac226960ca7faaa9c0dbdf30102f35034",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745923190,
      "headline": "Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets",
      "id": 134131498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=b94400337c2f6fa646f7a59b7eba5a7ac226960ca7faaa9c0dbdf30102f35034"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron",
    "summary": "Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=b533d00f3cfcfab75996e6f61bdb4111f0bc92aa9dbf9d909f8cdf7ce7accfce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745922720,
      "headline": "The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron",
      "id": 134130902,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=b533d00f3cfcfab75996e6f61bdb4111f0bc92aa9dbf9d909f8cdf7ce7accfce"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Reports First Quarter 2025 Financial and Operating Results",
    "summary": "First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024First quarter 2025 EYLEA HD® U.S. net sales increased 54% to $307 million versus first quarter 2024; total EYLEA HD and EYLEA® U.S. net sales decreased 26% to $1.04 billion Dupixent approved for chronic spontaneous urticaria (CSU) in U.S.; approved for chronic obstructi",
    "url": "https://finnhub.io/api/news?id=fa8a0cb24894e5693c9032b24828af839e9977e80225b509c06d0155349e53ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745922600,
      "headline": "Regeneron Reports First Quarter 2025 Financial and Operating Results",
      "id": 134131500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024First quarter 2025 EYLEA HD® U.S. net sales increased 54% to $307 million versus first quarter 2024; total EYLEA HD and EYLEA® U.S. net sales decreased 26% to $1.04 billion Dupixent approved for chronic spontaneous urticaria (CSU) in U.S.; approved for chronic obstructi",
      "url": "https://finnhub.io/api/news?id=fa8a0cb24894e5693c9032b24828af839e9977e80225b509c06d0155349e53ed"
    }
  },
  {
    "ts": null,
    "headline": "EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma",
    "summary": "The decision is underpinned by outcomes from the LINKER-MM1 trial at a 200mg dose of the antibody.",
    "url": "https://finnhub.io/api/news?id=c9766dde68ac41b310d5f3c1b44319aa7a6776d6985a1a7de1b28eb4e9475671",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745919345,
      "headline": "EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma",
      "id": 134131501,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The decision is underpinned by outcomes from the LINKER-MM1 trial at a 200mg dose of the antibody.",
      "url": "https://finnhub.io/api/news?id=c9766dde68ac41b310d5f3c1b44319aa7a6776d6985a1a7de1b28eb4e9475671"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals : Apr 2025 - REGN Corporate Presentation",
    "summary": "Regeneron Corporate Presentation A P R I L 2 0 2 5 This non-promotional presentation contains investigational data as well as forward-loofiing statements;...",
    "url": "https://finnhub.io/api/news?id=b5e85c1f0f1ee44f82b8639c81ffc29d2fa9da6fa997a061feb03e48bcc00e98",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745915303,
      "headline": "Regeneron Pharmaceuticals : Apr 2025 - REGN Corporate Presentation",
      "id": 134124854,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Corporate Presentation A P R I L 2 0 2 5 This non-promotional presentation contains investigational data as well as forward-loofiing statements;...",
      "url": "https://finnhub.io/api/news?id=b5e85c1f0f1ee44f82b8639c81ffc29d2fa9da6fa997a061feb03e48bcc00e98"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharma's first-quarter results miss on lower Eylea demand",
    "summary": "Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket...",
    "url": "https://finnhub.io/api/news?id=7b3d444a9cedb5ccb8ed12ea062824496f179ae78d7d4ae5cbc7b81caea51dda",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745915278,
      "headline": "Regeneron Pharma's first-quarter results miss on lower Eylea demand",
      "id": 134124868,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket...",
      "url": "https://finnhub.io/api/news?id=7b3d444a9cedb5ccb8ed12ea062824496f179ae78d7d4ae5cbc7b81caea51dda"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. - EYLEA HD Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease",
    "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD Injection 8 mg in wet age-related macular...",
    "url": "https://finnhub.io/api/news?id=e5773bd060e28e982956ad67c15050073f24e103dbd56fbf46ef722a473c60ef",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745913384,
      "headline": "Regeneron Pharmaceuticals, Inc. - EYLEA HD Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease",
      "id": 134124519,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD Injection 8 mg in wet age-related macular...",
      "url": "https://finnhub.io/api/news?id=e5773bd060e28e982956ad67c15050073f24e103dbd56fbf46ef722a473c60ef"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. - Lynozyfic Approved in the European Union for the Treatment of Relapsed, Refractory Multiple Myeloma",
    "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted conditional marketing approval of Lynozyfic to treat adults with relapsed and refractory ...",
    "url": "https://finnhub.io/api/news?id=ff3e45f3c11dd149f50229dfeda49b4a6a2cf050a0b8d13fbd8510d2b2e6746c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745913313,
      "headline": "Regeneron Pharmaceuticals, Inc. - Lynozyfic Approved in the European Union for the Treatment of Relapsed, Refractory Multiple Myeloma",
      "id": 134124514,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted conditional marketing approval of Lynozyfic to treat adults with relapsed and refractory ...",
      "url": "https://finnhub.io/api/news?id=ff3e45f3c11dd149f50229dfeda49b4a6a2cf050a0b8d13fbd8510d2b2e6746c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed",
    "summary": "By Rob Curran Regeneron Pharmaceuticals' first-quarter net income rose but revenue fell due to inventory issues and generic competition for its best-selling biopharmaceuticals, and the company...",
    "url": "https://finnhub.io/api/news?id=e448e6dcc915892a79e640734f17deb4309f7b3373b5f74ff69265b6580fe12b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745910501,
      "headline": "Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed",
      "id": 134124153,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Rob Curran Regeneron Pharmaceuticals' first-quarter net income rose but revenue fell due to inventory issues and generic competition for its best-selling biopharmaceuticals, and the company...",
      "url": "https://finnhub.io/api/news?id=e448e6dcc915892a79e640734f17deb4309f7b3373b5f74ff69265b6580fe12b"
    }
  },
  {
    "ts": null,
    "headline": "Alphabet Sets A Positive Tone Ahead Of Mega Tech Earnings Results This Week",
    "summary": "With 12% of S&P 500 companies reporting for the Q1 reporting season, EPS growth currently stands at 10.1%. Read more here.",
    "url": "https://finnhub.io/api/news?id=dc13ebbfecea942308757fd0ac43260ba4092619f845854fd643fdea3987fe21",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745892900,
      "headline": "Alphabet Sets A Positive Tone Ahead Of Mega Tech Earnings Results This Week",
      "id": 134122014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1169706295/image_1169706295.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "With 12% of S&P 500 companies reporting for the Q1 reporting season, EPS growth currently stands at 10.1%. Read more here.",
      "url": "https://finnhub.io/api/news?id=dc13ebbfecea942308757fd0ac43260ba4092619f845854fd643fdea3987fe21"
    }
  }
]